Just how useful is it to get access to a pharmaceutical company compound? Back in 2012 Dr Richard Mead of the University of Sheffield was one of 15 academic project leaders funded by the MRC to research an alternative use for a compound no longer being developed by AstraZeneca. As we launch the next round of the MRC-Industry Asset Sharing Initiative he tells us how the collaboration has brought together the best of both worlds.
Copyright: Richard Mead
I’m no stranger to the pharmaceutical industry. I spent three years in drug development at Celltech in the early 2000s. But even with my experience, it’s still amazing to be reminded of the resources that pharmaceutical companies have at their fingertips. It sounds obvious, but their access to unique compounds, and their ability to make them, is impressive. Read more
Jennifer Lawson is the Trials Manager for the recently launched Deep and Frequent Phenotyping study looking to do the most in-depth research ever conducted to find out how Alzheimer’s disease develops. She is part of Professor Simon Lovestone’s Translational Neuroscience and Dementia Research group at the University of Oxford.
Career in brief
- Psychology BSc
- Worked at the Oxford Mental Health Trust as a Research Coordinator
- Part time Cognitive Neuroscience MSc whilst working full time at the Trust
- Managed the feasibility study that has led to this Deep and Frequent Phenotyping study
My career path has been slightly unusual. Like many of my peers studying psychology, I planned to become a clinical psychologist. So I went to gain experience working in Oxford Health NHS Foundation Trust, assisting with clinical trials and other research studies.
Charity partners Alzheimer’s Society and Alzheimer’s Research UK will be instrumental in involving people living with dementia in the work of the new £250m MRC-led UK Dementia Research Institute. Here Alzheimer’s Society Ambassador Keith Oliver shares his hopes for how the new institute will make life better for people with dementia, now and tomorrow.
Photo copyright: Alzheimer’s Society
My world changed in 2010 when I was diagnosed with early-onset Alzheimer’s disease at the age of 55. My early symptoms were falling over, an element of reduced concentration and being unable to follow things as well as I did previously.
I went to the GP thinking I’d got an ear infection and was sent for an MRI scan. When I had an appointment with a neurologist to discuss the scan he said, totally out of the blue, that it looked like the early stages of Alzheimer’s disease. After attending a memory clinic for around four months of quite intensive testing and assessments I received a diagnosis. Read more